Lupin scales record high
Lupin rose 2.24% to Rs 800 at 14:36 IST on BSE, with the stock extending recent rally triggered by the company reporting strong Q4 earnings.
Meanwhile, the S&P BSE Sensex was up 74.70 points or 0.37% at 20,287.66.
On BSE, 1.93 lakh shares were traded in the counter as against average daily volume of 66,009 shares in the past one quarter.
The stock hit a high of Rs 801.25 so far during the day, which is a record high for the counter. The stock hit a low of Rs 764.85 so far during the day. The stock had hit a 52-week low of Rs 507 on 15 June 2012.
The stock had outperformed the market over the past one month till 15 May 2013, surging 19.05% compared with the Sensex's 10.11% rally. The scrip had also outperformed the market in past one quarter, jumping 33.38% as against Sensex's 3.83% rise.
The large-cap company has equity capital of Rs 89.53 crore. Face value per share is Rs 2.
Shares of Lupin have rallied 12.14% in eight trading sessions from Rs 713.35 on 7 May 2013, after the company during trading hours on 8 May 2013, reported strong Q4 results.
Lupin's consolidated net profit jumped 162.2% to Rs 408.08 crore on 34.7% growth in net sales to Rs 2537.35 crore in Q4 March 2013 over Q4 March 2012.
Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and Cephalosporin segment.
Powered by Capital Market - Live News